Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04729972
Recruitment Status : Completed
First Posted : January 29, 2021
Last Update Posted : February 8, 2023
Sponsor:
Collaborator:
The Lowy Medical Research Institute Limited
Information provided by (Responsible Party):
Neurotech Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.

Condition or disease Intervention/treatment Phase
Macular Telangiectasia Type 2 Combination Product: NT-501 CNTF implant Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2
Actual Study Start Date : August 13, 2021
Actual Primary Completion Date : December 23, 2022
Actual Study Completion Date : December 23, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: NT-501 CNTF Implant
Participants from the NTMT-01/02 Extenstion study or participants from the NTMT-03 study which received an implant Studies with a CNFT implant in one eye will receive an implant in the fellow eye
 Combination Product: NT-501 CNTF implant
Single implantation of CNTF-secreting NT-501 device into one eye


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Ocular and Systemic Safety [ Time Frame: 6 months ]
    The number and severity of adverse events , systemic and ocular ,from baseline through six months post-implantation.


Secondary Outcome Measures :
  1. Best correct visual acuity [ Time Frame: 6 months ]
    Changes in visual acuity and retinal imaging with optical coherence tomography (OCT).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria

  1. Participants from the NTMT-03 study must have completed the Month-24 visit
  2. Participant in the MacTel Phase 1/2 extension (NTMT-01/02E) study or the Phase 3 study must exit these studies prior to entering the Bilateral Implant safety study (NTMT-02B)
  3. Participant must be willing and able to follow the study instructions and be willing and able to complete all required study procedures and visits
  4. Participant must be willing and able to provide a signed Informed Consent, as well as written documentation in accordance with the relevant country and local privacy requirements, e.g., written data protection consent
  5. Females of childbearing potential must consent to a pregnancy test before entering the study
  6. A participant's refusal to allow the collection of blood samples for analysis of serum CNTF, serum Ab or Nab to CNTF, Ab to NTC-201.6A cells and Ab to DFHR levels in one eye will not exclude the participant from study participation

Ocular Inclusion Criteria

  1. Participant must have a positive diagnosis of MacTel type 2 with evidence of fluorescein leakage typical of MacTel and at least one of the other features that include hyperpigmentation that is outside of a 500-micron radius from the center of the fovea, retinal opacification, crystalline deposits, right-angle vessels, or inner/outer lamellar cavities in the study eye
  2. Participant must have steady fixation in the foveal or parafoveal area in the study eye and sufficiently clear media for good quality photographs

General Exclusion Criteria

  1. Females of childbearing potential (those who are not surgically sterilized or post- menopausal, i.e., absence of menstruation for 12 months or longer) may not participate in the study if any of the following conditions exists:

    • Pregnant (positive pregnancy test at Visit 1 or intend to become pregnant during the study)
    • Nursing (lactating)
    • Do not agree to use adequate birth control methods for the duration of the study and until 90 days after the last administration of study drug (adequate birth control methods are: hormonal - oral, implantable, transdermal or injectable contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm, intrauterine device [IUD] or surgical sterilization of partner, or total sexual abstinence)
  2. Participant is too ill to likely complete the entire study, based on the investigator's assessment
  3. Participant, in the opinion of the investigator, is not suitable for study participation
  4. Participant with any screening laboratory finding (serum chemistry, hematology, urinalysis) that in the opinion of the investigator is not suitable for study participation
  5. Participant has a history or current evidence of severe hypersensitivity to the NT-501 implant
  6. Participant has a history or current evidence of a medical condition (systemic or ophthalmic disease, metabolic dysfunction, physical examination finding or clinical laboratory finding) that may in the opinion of the investigator preclude the safe administration of the NT-501 implant or adherence to the scheduled study visits, safe participation in the study or affect the results of the study (e.g., unstable or progressive cardiovascular, cerebral vascular, pulmonary, Parkinson's, liver or renal disease; depression, cancer, or dementia

Ocular Exclusion Criteria

  1. Participant has a history or evidence of the following surgeries/procedures in the study eye, as assessed at Visit 1, including:

    • Submacular surgery
    • Vitrectomy
    • Retinal detachment
    • Incisional glaucoma surgery
    • Trabeculectomy or trabeculoplasty
    • Cataract surgery or laser-assisted in situ keratomileusis (LASIK) performed in the previous 6 months
  2. Participant has uncontrolled glaucoma; or ocular hypertension, i.e., IOP ≥ 25 mmHg in the study eye
  3. Participant has evidence of intraretinal or subretinal neovascularization or central serous chorioretinopathy in the study eye
  4. Participant has evidence of ocular disorder(s) in the study eye of a severity that could confound the interpretation of study results, compromise visual acuity or require medical or surgical intervention during the study period, including retinal vascular occlusion, severe nonproliferative or proliferative diabetic retinopathy, retinal detachment, macular hole, geographic atrophy, intraretinal or subretinal neovascularization, central serous chorio-retinopathy, pathological myopia
  5. Participant has a vitreous hemorrhage in the study eye at Visit 1 (Screening)
  6. Participant has a spherical equivalent of the refractive error in the study eye demonstrating more than 8 diopters of myopia
  7. Participant has a history or evidence of penetrating ocular trauma in the study eye
  8. Participant has an anticipated need for cataract extraction in the study eye within 6 months of Visit 1 (Screening) such as cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the Age-Related Eye Disease Study (AREDS) clinical lens grading system
  9. Participant has uveitis, history of uveitis in either eye or history of ocular herpes virus in either eye
  10. Participant has undergone major surgery within the last 6 months (systemic or ocular in either eye) or who are likely to require major surgery within 6 months of Visit 1 (Screening)
  11. Participant has periocular or ocular/intraocular infection or inflammation in either eye (such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis) within 3 months prior to Visit 1 (Screening)
  12. Participant has ocular hypotension in either eye (<6 mmHg) that in the opinion of the Investigator would interfere with the NT-501 implant insertion
  13. Participant has a history of scleritis, scleral thinning, periocular, ocular, or intraocular infection or inflammation, cicatrizing conjunctival diseases any other ocular conditions in the study eye that could interfere with or complicate the surgery associated with NT-501implant insertion
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04729972


Locations
Layout table for location information
United States, California
Jules Stein Eye Institute
Los Angeles, California, United States, 90095
United States, District of Columbia
National Eye Institute
Washington, District of Columbia, United States, 20892
United States, Florida
Bascom Palmer
Miami, Florida, United States, 33136
United States, Massachusetts
Massachusetts Eye and Ear Infirmary, Retina Service
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan, United States, 48105
United States, Ohio
Retina Associates of Cleveland, Inc.
Beachwood, Ohio, United States, 44122
United States, Texas
Retina Consultants of Texas
Houston, Texas, United States, 77030
Australia, New South Wales
Save Sight Institute
Sydney, New South Wales, Australia
Australia, Victoria
Centre for Eye Research Australia
East Melbourne, Victoria, Australia, 3002
Australia, Western Australia
Lions Eye Institute
Nedlands, Western Australia, Australia, 6009
Sponsors and Collaborators
Neurotech Pharmaceuticals
The Lowy Medical Research Institute Limited
Investigators
Layout table for investigator information
Study Chair: Thomas Hohman, PhD Neurotech Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Neurotech Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04729972    
Other Study ID Numbers: NTMT-02B
First Posted: January 29, 2021    Key Record Dates
Last Update Posted: February 8, 2023
Last Verified: February 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Neurotech Pharmaceuticals:
Macular Telangiectasia Type 2
CNTF
Mactel
Additional relevant MeSH terms:
Layout table for MeSH terms
Telangiectasis
Vascular Diseases
Cardiovascular Diseases